Biden's Prostate Cancer Transparency
The statement from Mr. Biden's office said he was diagnosed Friday after being seen 'for a new finding of a prostate nodule after experiencing increasing urinary symptoms.' When did his symptoms start? A spokesman told the press Tuesday that Mr. Biden's last known PSA blood test, which screens for prostate specific antigen, was in 2014. Why? Could another test have caught the cancer earlier?
One prominent oncologist, Obama Administration veteran Ezekiel Emanuel, offered an unsettling medical assessment on MSNBC. 'He's had this for many years, maybe even a decade, growing there and spreading,' Dr. Emanuel said. 'It's a little surprising. I looked back at the records, and there's no evidence that when he got his health status, and the medical records were released, that he had a prostate specific antigen.'
That blood test isn't perfect, and other doctors quoted in the press say they've had patients develop aggressive cancers like Mr. Biden's, despite clean PSA tests. Mr. Biden was 78 when he was sworn in as President. The U.S. Preventive Services Task Force currently recommends against PSA screening of patients 70 and older, saying that the potential harms outweigh the benefits for a population that already has a heightened risk of mortality from all causes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
WATCH: President Donald Trump struggles to pronounce Tua Tagovailoa's name
Pronunciation guides are your friend. That's the lesson that President Donald Trump learned on Thursday when he was faced with the challenge of pronouncing Tua Tagovailoa's name. It wasn't particularly close from the commander-in-chief, who butchered the last name of the Miami Dolphins' quarterback. Take a look: Trump was announcing that he has reestablished the Presidential Fitness Test, which went away at the end of the 2012-13 school year. In doing so, the president also established a council that includes professional athletes, with Tagovailoa also being involved. 'Saquon Barkley is on the council, and Tua Tagovailoa [tag-oh-vah-lee-ah], the quarterback who is … really he's been fantastic, … when he's not injured," Trump said. "He's got to stay healthy,' Trump isn't the first – and likely won't be the last – to struggle with the pronunciation, but to his credit, the president battled through it. Like a classic politician, Trump quickly pivoted and turned the attention to the quarterback's health – making it seem as though he wasn't tripped up on the pronunciation. This article originally appeared on USA TODAY: WATCH: President Donald Trump butchers Tua Tagovailoa's name
Yahoo
44 minutes ago
- Yahoo
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
